By Doug Young & Rene Vanguestaine

The latest annual survey by the EU Chamber of Commerce in China shows revenue fell for more European businesses’ China operations last year. Is this a watershed moment for China’s economy, showing the days of western enthusiasm for investing in the country will never return to pre-covid levels? And AstraZeneca has become the latest major company to weigh a potential spinoff of its China unit. Is this the beginning of a trend?

About China Inc

China Inc by Bamboo Works discusses the latest developments on Chinese companies listed in Hong Kong and the United States to drive informed decision-making for investors and others interested in this dynamic group of companies.

Subscribe to China Inc on your favorite app:

Apple Podcasts Spotify

Recent Articles

Seres makes new energy vehicles

Seres takes control of Aito brand from Huawei alliance

New energy vehicle (NEV) maker Seres Group Co. Ltd. (9927.HK; 601127.SH) has taken full control of its Aito brand from partner Huawei, the pair announced on Tuesday. The move sharply…
Tinci IPO gets CSRC approval

Is Tinci Materials limping to a Hong Kong IPO?

China’s securities regulator has given the green light to the battery materials maker’s Hong Kong listing application, but only after a year of scrutiny Key Takeaways: Tinci Materials has been…